Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA has safety and efficacy concerns in accelerated approval of Kyprolis for multiple myeloma

This article was originally published in Scrip

Executive Summary

Onyx Pharmaceuticals' hopes for a quick market launch of its second generation proteasome inhibitor Kyprolis (carfilzomib) were dimmed on 18 June, when the US FDA released its highly sceptical analysis of the company's request for accelerated approval of the drug for patients with relapsed and refractory multiple myeloma. The FDA concluded that "the risks of carfilzomib may not outweigh its benefits".






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts